De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
Nu Skin Enterprises Beheer
Beheer criteriumcontroles 2/4
De CEO Nu Skin Enterprises' is Ryan Napierski, benoemd in Mar2017, heeft een ambtstermijn van 7.58 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 5.84M, bestaande uit 17% salaris en 83% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.21% van de aandelen van het bedrijf, ter waarde $ 767.99K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 12 jaar en 12 jaar.
Belangrijke informatie
Ryan Napierski
Algemeen directeur
US$5.8m
Totale compensatie
| Percentage CEO-salaris | 17.0% |
| Dienstverband CEO | 7.6yrs |
| Eigendom CEO | 0.2% |
| Management gemiddelde ambtstermijn | 12yrs |
| Gemiddelde ambtstermijn bestuur | 12yrs |
Recente managementupdates
Recent updates
Nu Skin Enterprises' (NYSE:NUS) Returns On Capital Not Reflecting Well On The Business
Aug 31
Insufficient Growth At Nu Skin Enterprises, Inc. (NYSE:NUS) Hampers Share Price
Aug 13Nu Skin Enterprises, Inc.'s (NYSE:NUS) CEO Might Not Expect Shareholders To Be So Generous This Year
May 30Is Nu Skin Enterprises (NYSE:NUS) Using Too Much Debt?
May 13Capital Allocation Trends At Nu Skin Enterprises (NYSE:NUS) Aren't Ideal
Mar 28Nu Skin: A Sell Signal Amidst Industry Decline And Strategic Uncertainty
Mar 04We Think You Can Look Beyond Nu Skin Enterprises' (NYSE:NUS) Lackluster Earnings
Feb 22Nu Skin Enterprises' (NYSE:NUS) Dividend Will Be Reduced To $0.06
Feb 19Analysts Just Shaved Their Nu Skin Enterprises, Inc. (NYSE:NUS) Forecasts Dramatically
Feb 18Nu Skin Enterprises, Inc. (NYSE:NUS) Could Be Riskier Than It Looks
Jan 18Nu Skin Enterprises (NYSE:NUS) Has A Somewhat Strained Balance Sheet
Dec 14Nu Skin Enterprises (NYSE:NUS) Has Affirmed Its Dividend Of $0.39
Nov 17Nu Skin: Is It Just A Growth Problem?
Oct 17Nu Skin Enterprises (NYSE:NUS) Could Be At Risk Of Shrinking As A Company
Oct 09When Should You Buy Nu Skin Enterprises, Inc. (NYSE:NUS)?
Sep 27Nu Skin: Attractive Valuation Trumps Near-Term Risks
Sep 12Nu Skin Enterprises (NYSE:NUS) Takes On Some Risk With Its Use Of Debt
Sep 08Nu Skin Enterprises (NYSE:NUS) Has Announced A Dividend Of $0.39
Aug 05Is Nu Skin Enterprises, Inc. (NYSE:NUS) Expensive For A Reason? A Look At Its Intrinsic Value
Jul 31Nu Skin: A High-Risk/High-Reward Turnaround Play Worth The Risks
Jun 26Is Now The Time To Look At Buying Nu Skin Enterprises, Inc. (NYSE:NUS)?
Jun 23We Think Nu Skin Enterprises (NYSE:NUS) Is Taking Some Risk With Its Debt
May 22Nu Skin Enterprises (NYSE:NUS) Will Pay A Dividend Of $0.39
May 07Nu Skin Enterprises (NYSE:NUS) Could Be Struggling To Allocate Capital
Apr 26Why Nu Skin Enterprises, Inc. (NYSE:NUS) Could Be Worth Watching
Mar 18Nu Skin Enterprises (NYSE:NUS) Will Pay A Larger Dividend Than Last Year At $0.39
Feb 19Nu Skin raises quarterly dividend by 1.3% to $0.39/share
Feb 15These 4 Measures Indicate That Nu Skin Enterprises (NYSE:NUS) Is Using Debt Reasonably Well
Feb 12Returns On Capital At Nu Skin Enterprises (NYSE:NUS) Paint A Concerning Picture
Jan 25Is Now The Time To Look At Buying Nu Skin Enterprises, Inc. (NYSE:NUS)?
Dec 04Nu Skin Enterprises (NYSE:NUS) Will Pay A Dividend Of $0.385
Nov 17Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$148m |
| Mar 31 2024 | n/a | n/a | -US$3m |
| Dec 31 2023 | US$6m | US$992k | US$9m |
| Sep 30 2023 | n/a | n/a | US$59m |
| Jun 30 2023 | n/a | n/a | US$70m |
| Mar 31 2023 | n/a | n/a | US$77m |
| Dec 31 2022 | US$5m | US$942k | US$105m |
| Sep 30 2022 | n/a | n/a | US$38m |
| Jun 30 2022 | n/a | n/a | US$113m |
| Mar 31 2022 | n/a | n/a | US$139m |
| Dec 31 2021 | US$5m | US$801k | US$147m |
| Sep 30 2021 | n/a | n/a | US$230m |
| Jun 30 2021 | n/a | n/a | US$237m |
| Mar 31 2021 | n/a | n/a | US$219m |
| Dec 31 2020 | US$4m | US$721k | US$191m |
| Sep 30 2020 | n/a | n/a | US$158m |
| Jun 30 2020 | n/a | n/a | US$146m |
| Mar 31 2020 | n/a | n/a | US$150m |
| Dec 31 2019 | US$2m | US$688k | US$174m |
| Sep 30 2019 | n/a | n/a | US$116m |
| Jun 30 2019 | n/a | n/a | US$125m |
| Mar 31 2019 | n/a | n/a | US$129m |
| Dec 31 2018 | US$3m | US$621k | US$122m |
| Sep 30 2018 | n/a | n/a | US$158m |
| Jun 30 2018 | n/a | n/a | US$146m |
| Mar 31 2018 | n/a | n/a | US$137m |
| Dec 31 2017 | US$3m | US$594k | US$129m |
Compensatie versus markt: De totale vergoeding ($USD 5.84M ) Ryan } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 2.40M ).
Compensatie versus inkomsten: De vergoeding van Ryan is gestegen terwijl het bedrijf verliesgevend is.
CEO
Ryan Napierski (50 yo)
7.6yrs
Tenure
US$5,838,579
Compensatie
Mr. Ryan S. Napierski has been Chief Executive Officer of Nu Skin Enterprises Inc. since September 1, 2021. Mr. Napierski has been the President of Nu Skin Enterprises Inc. since March 7, 2017 and has been...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Co-Founder & Executive Chairman of the Board | 28.8yrs | US$856.61k | 0.24% $ 847.6k | |
| President | 7.6yrs | US$5.84m | 0.21% $ 740.9k | |
| Executive VP | 5.2yrs | US$1.86m | 0.14% $ 511.9k | |
| Executive VP & Chief Scientific Officer | 18.7yrs | US$1.12m | 0.19% $ 657.2k | |
| Executive VP & General Counsel | 3.2yrs | US$2.28m | 0.32% $ 1.1m | |
| Executive VP & Chief Product Officer | 6.8yrs | US$1.41m | 0.19% $ 683.6k | |
| Founder | 40.8yrs | US$621.69k | geen gegevens | |
| Founder | 28.8yrs | US$1.06m | geen gegevens | |
| Senior VP & CTO | 3.8yrs | geen gegevens | geen gegevens | |
| Chief Information Officer | 18.7yrs | geen gegevens | geen gegevens | |
| Vice President of Investor Relations | no data | geen gegevens | geen gegevens | |
| Chief Marketing Officer | 16.4yrs | geen gegevens | geen gegevens |
12.0yrs
Gemiddelde duur
66yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van NUS is doorgewinterd en ervaren (gemiddelde ambtstermijn van 12 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Co-Founder & Executive Chairman of the Board | 28.8yrs | US$856.61k | 0.24% $ 847.6k | |
| President | 3.3yrs | US$5.84m | 0.21% $ 740.9k | |
| Independent Director | 9.3yrs | US$273.20k | 0.033% $ 116.9k | |
| Lead Independent Director | 27.6yrs | US$280.20k | 0.21% $ 751.5k | |
| Member of Anti-Aging Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
| Independent Director | 16.3yrs | US$257.08k | 0.15% $ 513.2k | |
| Member of the Anti-Aging Scientific Advisory Board | 14.8yrs | geen gegevens | geen gegevens | |
| Member of Anti-Aging Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
| Member of Anti-aging Scientific Advisory Board | 15yrs | geen gegevens | geen gegevens | |
| Director | 8.3yrs | US$249.20k | 0.044% $ 155.5k | |
| Independent Director | 5.3yrs | US$268.20k | 0.044% $ 153.8k | |
| Independent Director | 3.3yrs | US$264.33k | 0.039% $ 136.7k |
12.0yrs
Gemiddelde duur
67.5yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van NUS zijn ervaren en ervaren (gemiddelde ambtstermijn van 12 jaar).